Annual Newsletter 2017

Download a copy here. Newsletter_Autumn_2017.pdf

Latest

Kilimanjaro Charity Climb Ball

Join CPT supporter David Baker at his wonderful Kilimanjaro Charity Climb Ball at Onley Grounds Farm in Warwickshire in support of CPT.
**Webinar** - Targeting the Genetics of Parkinson's

In this third in our collaborative webinar series with the Journal of Parkinson's and Parkinson's Movement, Professor Patrik Brundin, Dr Gaurav Gupta, Dr Ziv Gan-or Dr Roy Alcalay, Jonathon Silverstein and Ben Stecher discuss the genetics of Parkinson's...
New Sub-types of Parkinson's Proposed

A UK-wide study involving over 2500 people with recently diagnosed Parkinson's has identified four novel 'clusters' or groupings based on their clinical features.
Jeremy Davies takes on 1700 mile cycle from Amble to Slovenia

On 17th August, Jeremy Davies set off on an epic cycle from his hometown of Amble all the way to Ljubljana, Slovenia to raise funds and awareness for CPT.

**Webinar** - Targeting the Genetics of Parkinson's

In this third in our collaborative webinar series with the Journal of Parkinson's and Parkinson's Movement, Professor Patrik Brundin, Dr Gaurav Gupta, Dr Ziv Gan-or Dr Roy Alcalay, Jonathon Silverstein and Ben Stecher discuss the genetics of Parkinson's...
New Sub-types of Parkinson's Proposed

A UK-wide study involving over 2500 people with recently diagnosed Parkinson's has identified four novel 'clusters' or groupings based on their clinical features.
A Vaccine for Parkinson's - Developments in Immunotherapy

When misfolded, the protein alpha-synuclein becomes toxic to neurons and is a key pathological culprit in Parkinson’s. It is therefore an important target for disease-modification. Immunotherapy in Parkinson's attempts to use immune cells, and specifically the antibodies they generate, to target misfolded alpha-synuclein to inactivate it.
The SPHERE Parkinson's Measuring Project

An innovative Parkinson's measurement and monitoring project using wearable health apps and sensors set up in a home environment is being developed at the University of Bristol.
The Power of the Parkinson’s Patient According to Tom Isaacs - By Soania Mathur

Soania Mathur was, like former President of CPT Tom Isaacs, diagnosed with Young Onset Parkinson's at just 27. For Soania, Tom’s core principles of supporting people with Parkinson’s in becoming active participants in the search for better treatments, key to finding a cure.
The Cancer Enzyme Involved in Parkinson's

Researchers at the Johns Hopkins School of Medicine have published a research report that points not only towards a specific pathway of neurodegeneration for Parkinson's, but also highlights a therapeutic target for which clinically-approved drugs are already available.
'Cooling' Inflamed Brains in Parkinson's

When cells in the body become unwell or injured, they release proteins that inform the body of their stricken situation. These activate the release of further signalling proteins called inflammasomes...
The Epitomical 'Mover & Shaker'

A Special Issue of the European Journal of Neuroscience in memory of late President and Co-founder Tom Isaacs has been compiled by NECTAR and this article by Tom's wife Lyndsey heralds this collaboration...
The Appendix and Parkinson's - Are we Better Off Without One?

The human appendix was long considered functionless and a bit of an oddity. Some people even thought of it as an accident of evolution. More recently, however, our ideas regarding the appendix have changed. And a new study published this week suggests that the appendix may even be influential in some cases of Parkinson's.
Gene Therapy Approaches for Parkinson's

Two biotech companies have recently presented updates in their gene therapy treatment trials. Read more...

Breakthrough in stem cell treatment for Parkinson's

In a major breakthrough for the treatment of Parkinson's, researchers working with laboratory rats show it is possible to make dopamine cells from embryonic stem cells and transplant them into the brain.
Tom Isaacs

We are devastated to announce that Tom Isaacs, President and Co-founder of The Cure Parkinson’s Trust (CPT) died on Wednesday morning (31st May). Tom’s passing was unexpected and swift.
New Evidence Suggests Parkinson's Might Not Start in The Brain

A new study adds to a raft of new evidence which suggests Parkinson's starts in the gut.
Trials - Repurposed drugs

Our international Linked Clinical Trials initiative (LCT) identifies potential new treatments to slow, stop or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions.
Science news

Read the latest Parkinson's science and research news here.
Stem Cell Therapies - Research Updates

When diagnosed, people with Parkinson’s have often had the disease for years and have lost over half of the dopamine producing cells in their brain. Now scientists are searching for a way to replace these nerve cells.
Apply for Funding
The NAC Trial - the facts
Our story
Diabetes Drug Potential Disease-Modifying Therapy

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.

Science news

Read the latest Parkinson's science and research news here. Read more

The Cure Collective

The Cure Collective is an opportunity to join like-minded individuals who are committed to help drive forward the quest to find a cure for Parkinson’s... Read more

The Annual Review 2018

Our Annual Review 2018 - your online publication here... Read more

Parkinson's Movement

The Science of Parkinson's - Dr Simon Stott

Leave a gift in your Will

A donation to The Cure Parkinson's Trust will make a huge difference to our research to slow, stop or even reverse Parkinson's. Read more